Table 2.
Ongoing clinical trials of adoptive immunotherapy in Hodgkin lymphoma
| Treatment | Trial identifier | Trial site | Trial phase | Dose/conditioning | Study summary |
|---|---|---|---|---|---|
| CD30 CAR T cells | NCT03049449 | National Cancer Institute (NCI) | 1 | Dose: 0·3-1 × 106 cells/kg; conditioning: cyclophosphamide and fludarabine | Evaluate the safety and feasibility of anti-CD30 CARTs in patients with advanced CD30-expressing lymphomas |
| CD30 CAR T cells | ChiCTR2000041436 | Cancer Hospital of Guangxi Medical University, China | 1 | Not available | Evaluate the safety and efficacy of CAR T-cell therapy targeting CD19,CD20,CD22,CD30,CD79B,CD99,CD38,CD7, or BCMA for relapsed/refractory tumors of hematopoietic and lymphoid tissues |
| CD30 CAR T cells | NCT02690545 | UNC Lineberger Comprehensive Cancer Center | 1b/2 | Dose: 1-2 × 108 cells/m2; conditioning: bendamustine and fludarabine | Evaluate the safety and efficacy of CD30 CAR T-cells in patients with CD30+ R/R HL and NHL |
| CD30 CAR T cells | NCT02917083 | Baylor College of Medicine | 1 | Dose: 0·2-2 × 108 cells/m2; conditioning: cyclophosphamide and fludarabine | Evaluate the safety and efficacy of CD30 CAR T-cells in patients with CD30+ R/R HL and NHL |
| CD30.CCR4 CAR T cells | NCT03602157 | UNC Lineberger Comprehensive Cancer Center | 1 | Dose: 0·2-2 108 cells/m2; conditioning: fludarabine and bendamustine | Evaluate the safety and tolerability of CD30.CCR4 CAR T-cells +/− CD30 CAR T-cells in patients with R/R CD30+ HL or CTCL |
| CD30 and CD19 CAR T cells | ChiCTR2000028922 | The Third Affiliated Hospital of Kunming Medical University, China | Early phase 1 | Not available | Evaluate the feasibility and efficacy of combined use of CD19 and CD30 CAR T-cells in patients with R/R HL |
| CD30 CAR T cells | NCT02958410 | Southwest Hospital, China | 1/2 | Not available | Evaluate the safety and efficacy of CD30 CAR T cells in patients with R/R CD30+ lymphomas |
| CD30 CAR T cells | NCT04008394 | Wuhan Union Hospital, China | 1 | Not available | Evaluate the safety and efficacy of CD30 CAR T cells in patients with R/R CD30+ lymphomas |
| CD30 CAR T cells | ChiCTR-OPN-16009069 | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China | 1 | Not available | Evaluate the safety and efficacy of CD30 CAR T cells in patients with R/R CD30+ lymphomas |
| CD30 CAR T cells | NCT02663297 | UNC Lineberger Comprehensive Cancer Center | 1 | Dose: 0·2-2 × 108 cells/m2 | Evaluate the safety and tolerability of CD30 CAR T-cells for prevention of relapse after autologous stem cell transplant in patients with CD30+ lymphomas |
| CD30 CAR T cells | NCT04653649 | l'Hospital de la Santa Creu i Sant Pau, Spain | 1/2a | Dose: 3-10 × 106/kg | Evaluate the safety, maximum-tolerated dose, and response rate of CD30 CAR T-cells in patients with R/R CD30+ HL or NHL |
| EBV CTLs expressing CD30 CARs | NCT01192464 | Baylor College of Medicine | 1 | Dose: 0·2-1 × 108 cells/m2 | Evaluate the safety and efficacy of autologous EBV-specific cytotoxic T-lymphocytes genetically modified to express a CD30 CAR in patients with R/R HL or NHL |
| Allogeneic CD30 CAR EBV-specific T lymphocytes | NCT04288726 | Baylor College of Medicine | 1 | Dose: 0·4-4 × 108 cells/m2 | Evaluate the dose-limiting toxicity rate and response to allogeneic CD30 CARs engineered onto EBV-specific T cells in patients with CD30+ HL, NHL, ALCL, or peripheral T-cell lymphoma |
| CD30 CAR T cells | ChiCTR2000030843 | Beijing Boren Hospital, China | Early phase 1 | Not available | Evaluate the safety and efficacy of CD30 CAR T cells in patients with R/R CD30+ lymphomas |
| CD30 CAR T cells | NCT02259556 | Chinese PLA General Hospital, China | Phase 1/2 | Dose: not available; conditioning: cyclophosphamide and fludarabine | Evaluate the safety and efficacy of CD30 CAR T cells in patients with R/R CD30+ lymphomas |
| CD30 CAR T cells | NCT02274584 | Peking University Cancer Hospital, China and University of Florida | 1/2 | Not available | Evaluate the safety and efficacy of CD30 CAR T-cells engineered with a self-withdrawal mechanism (FKBP-iCasp9) in patients with R/R CD30+ lymphomas |
| CD30 CAR T cells | NCT04268706 | Tessa Therapeutics | 2 | Conditioning: fludarabine and bendamustine | Evaluate the safety and efficacy of CD30 CAR T-cells in patients with R/R CD30+ HL |
| LMP 1/2 CTLs | NCT01956084 | Children’s National Medical Center | 1 | Dose: 1-5 × 107 cells/m2 | Evaluate the dose-limiting toxicities and survival of LMP-specific CTLs in patients with EBV+HL or NHL after allogeneic stem cell transplant |
| PD-1 knockout EBV-CTLs | NCT03044743 | The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, China | 1/2 | Dose: 2 × 107 cells/kg; conditioning: fludarabine and cyclophosphamide | Evaluate the safety of EBV-CTLs that have been knocked out for PD1 by the CRISP-Cas9 system, in treating patients with EBV+ advanced malignancies |
| EBV CTLs | NCT01555892 | Baylor College of Medicine | 1 | Dose: 1 × 108 cells/m2 | Evaluate the toxicity of escalating doses and anti-viral/anti-tumor effects of autologous LMP, BARF1, and EBNA1-specific T-lymphocytes in patients with EBV-associated HL |
| Tumor-associated antigen-specific CTLs | NCT01333046 | Baylor College of Medicine | 1 | Dose: 0.5-2 × 107 cells/m2 | Evaluate the safety and expansion, persistence, and anti-tumor effects of adoptively-transferred tumor-associated antigen (PRAME, SSX, MAGE, NY-ESSO, Survivin) -specific CTLs +/− azacytidine in patients with R/R HL or NHL |
| LMP, BARF1, and EBNA1-specific CTLs | NCT02287311 | Baylor College of Medicine | 1 | Dose: 0.4-1.5 × 108 cells/m2; conditioning: cyclophosphamide and fludarabine if circulating T cells are high | Evaluate the safety and dose-limiting toxicity of banked allogeneic, partially HLA-matched rapid EBV-specific T cells in patients with R/R EBV+ HL or NHL |